4-methyl-N-3-(4-pyridin-4-yl-pyrimidin-2-yl)-benzene-1,3-diamine | 475587-35-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-N-3-(4-pyridin-4-yl-pyrimidin-2-yl)-benzene-1,3-diamine
• 英文别名: 4-methyl-N(3)-(4-pyridin-4-ylpyrimidin-2-yl)benzene-1,3-diamine；(5-Amino-2-methylphenyl)-(4-pyridin-4-yl-pyrimidin-2-yl)-amine；6-Methyl-N1-(4-(pyridin-4-yl)pyriMidin-2-yl)benzene-1,3-diaMine；4-methyl-3-N-(4-pyridin-4-ylpyrimidin-2-yl)benzene-1,3-diamine
• CAS: 475587-35-0
• 化学式: C₁₆H₁₅N₅
• 分子量: 277.329
• InChiKey: JZZKAAFEZYXCBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  525.0±60.0 °C(Predicted)
• 密度：
  1.266±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-methyl-N-3-(4-pyridin-4-yl-pyrimidin-2-yl)-benzene-1,3-diamine 、 间硝基苯甲酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 26.0h， 以91%的产率得到N-[4-methyl-3-(4-pyridin-4-ylpyrimidin-2-ylamino)-phenyl]-3-nitrobenzamide
  参考文献：
  名称：

  伊马替尼中间体和类似物合成的优化方法† ‡

  摘要：

  我们回顾了伊马替尼合成的经典合成方法，为制备一系列新的伊马替尼类似物提供了一种改进和优化的方法。所提出的方法有效地克服了某些有问题的步骤，节省了时间和劳力，提供了很高的产率和纯度，并具有用于合成许多类似物的潜力。所需胍盐4的形成，是伊马替尼合成的关键步骤之一，几乎是通过合适的苯胺3的盐酸盐与过量的熔融氰胺在没有任何溶剂的情况下反应而定量进行的。纯芳基胺中间体6a–d在亚当催化剂上用氢气将中间体嘧啶5a-d的硝基还原后，可以在很短的反应时间内定量获得。此外，这种优化方法的应用可以扩展到尼罗替尼及其类似物中间体的合成中。

  DOI：

  10.1039/c6ra09812f
• 作为产物：
  描述：

  N-(2-methyl-5-nitrophenyl)guanidinium hydrochloride 在 platinum(IV) oxide 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 25.5h， 生成 4-methyl-N-3-(4-pyridin-4-yl-pyrimidin-2-yl)-benzene-1,3-diamine
  参考文献：
  名称：

  伊马替尼中间体和类似物合成的优化方法† ‡

  摘要：

  我们回顾了伊马替尼合成的经典合成方法，为制备一系列新的伊马替尼类似物提供了一种改进和优化的方法。所提出的方法有效地克服了某些有问题的步骤，节省了时间和劳力，提供了很高的产率和纯度，并具有用于合成许多类似物的潜力。所需胍盐4的形成，是伊马替尼合成的关键步骤之一，几乎是通过合适的苯胺3的盐酸盐与过量的熔融氰胺在没有任何溶剂的情况下反应而定量进行的。纯芳基胺中间体6a–d在亚当催化剂上用氢气将中间体嘧啶5a-d的硝基还原后，可以在很短的反应时间内定量获得。此外，这种优化方法的应用可以扩展到尼罗替尼及其类似物中间体的合成中。

  DOI：

  10.1039/c6ra09812f

文献信息

• Pyrimidine Derivatives
  申请人：Klebl Bert

  公开号：US20080187575A1

  公开（公告）日：2008-08-07

  The present invention relates to pyrimidine derivatives, methods for their synthesis, and the use of said pyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferation disorders, cancer, leukemia, erectile dysfunction, cardiovascular diseases and disorders, inflammatory diseases, transplant rejection, immunological diseases, neuroimmunological diseases, autoimmune diseases, infective diseases including opportunistic infections, prion diseases and/or neuro-degeneration. Furthermore, the present invention relates to pharmaceutical compositions containing at least one pyrimidine derivative and/or pharmaceutically acceptable salts thereof as an active ingredient together with at least one pharmaceutically acceptable carrier, excipient or diluents as well as to methods for prophylaxis and/or treatment of the above-mentioned diseases and disorders.

  本发明涉及嘧啶衍生物，其合成方法，以及所述嘧啶衍生物作为药用活性剂的用途，特别是用于预防和/或治疗细胞增殖紊乱、癌症、白血病、勃起功能障碍、心血管疾病和紊乱、炎症性疾病、移植排斥、免疫性疾病、神经免疫性疾病、自身免疫性疾病、感染性疾病包括机会性感染、朊病和/或神经退行性疾病。此外，本发明涉及含有至少一种嘧啶衍生物和/或其药用可接受盐作为活性成分的药物组合物，以及用于预防和/或治疗上述疾病和紊乱的方法。
• Pyridylpyrimidine derivatives as effective compounds against prion diseases
  申请人：——

  公开号：US20030176443A1

  公开（公告）日：2003-09-18

  The present invention relates to pyridylpyrimidine derivatives of the general formula (I): 1 wherein R represents hydrogen or methyl and Z represents nitrogen containing functional groups, the use of the pyridylpyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of prion infections and prion diseases, as well as compositions containing at least one pyridylpyrimidine derivative and/or pharmaceutically acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating prion infections and prion diseases using said pyridylpyrimidine derivatives. Human cellular protein kinases, phosphatases and cellular signal transduction molecules are disclosed as targets for detecting, preventing and/or treating prion infections and diseases, especially BSE, vCJD, or CJD which can be inhibited by the inventive pyridylpyrimidine derivatives.

  本发明涉及一般式（I）的吡啶基嘧啶衍生物，其中R代表氢或甲基，Z代表含氮的功能基团，该吡啶基嘧啶衍生物作为药物活性剂的使用，特别是用于预防和/或治疗朊病毒感染和朊病，以及含有至少一种吡啶基嘧啶衍生物和/或其药学可接受的盐的组合物。此外，本发明还涉及使用所述吡啶基嘧啶衍生物预防和/或治疗朊病毒感染和朊病的方法。人类细胞蛋白激酶、磷酸酶和细胞信号转导分子被揭示为检测、预防和/或治疗朊病毒感染和疾病的靶点，特别是BSE、vCJD或CJD，这些疾病可以被本发明的吡啶基嘧啶衍生物抑制。
• PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR
  申请人：Yang Xuqing

  公开号：US20110319420A1

  公开（公告）日：2011-12-29

  The invention provides a new kind of dihydroindene amide compounds of general formula I or their pharmaceutically acceptable salts or prodrug thereof which can be used as protein kinase inhibitor. The invention provides a preparation method of the kind of compounds, the pharmaceutical compositions containing the compounds, the method for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR, using them as protein kinase inhibitor, and their preparation use of drug used for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR.

  本发明提供了一种新型的二氢茚酰胺化合物，其通式为I，或其药学上可接受的盐或前药，可用作蛋白激酶抑制剂。本发明还提供了制备该类化合物的方法，含有该化合物的药物组合物，使用它们作为蛋白激酶抑制剂预防或治疗与蛋白激酶活性异常相关的疾病的方法，特别是Abl、Bcr-Abl、c-Kit和PDGFR，以及用于预防或治疗与蛋白激酶活性异常相关的疾病的药物制备用途。
• Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor
  申请人：Yang Xuqing

  公开号：US08703771B2

  公开（公告）日：2014-04-22

  The invention provides a new kind of dihydroindene amide compounds of general formula I or their pharmaceutically acceptable salts or prodrug thereof which can be used as protein kinase inhibitor. The invention provides a preparation method of the kind of compounds, the pharmaceutical compositions containing the compounds, the method for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR, using them as protein kinase inhibitor, and their preparation use of drug used for preventing or curing the diseases related to the abnormity of activities of protein kinases, especially Abl, Bcr-Abl, c-Kit and PDGFR.

  该发明提供了一种新型的二氢吲哚酰胺化合物，其通式为I，或其药学上可接受的盐或前药，可用作蛋白激酶抑制剂。该发明提供了该类化合物的制备方法，含有该类化合物的制药组合物，使用它们作为蛋白激酶抑制剂预防或治疗与蛋白激酶活性异常相关的疾病，特别是Abl、Bcr-Abl、c-Kit和PDGFR，并且它们的制备用于预防或治疗与蛋白激酶活性异常相关的疾病，特别是Abl、Bcr-Abl、c-Kit和PDGFR的药物使用。
• Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases
  申请人：GPC Biotech AG

  公开号：EP1721609A2

  公开（公告）日：2006-11-15

  The present invention relates to pyridylpyrimidine derivatives of the general formula (I): wherein R represents hydrogen or methyl and Z represents nitrogen containing functional groups, the use of the pyridylpyrimidine derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of prion infections and prion diseases, as well as compositions containing at least one pyridylpyrimidine derivative and/or pharmaceutically acceptable salt thereof. Furthermore, the present invention is directed to methods for preventing and/or treating prion infections and prion diseases using said pyridylpyrimidine derivatives. Human cellular protein kinases, phosphatases and cellular signal transduction molecules are disclosed as targets for detecting, preventing and/or treating prion infections and diseases, especially BSE, vCJD, or CJD which can be inhibited by the inventive pyridylpyrimidine derivatives.

  本发明涉及通式（I）的吡啶嘧啶衍生物： 其中 R 代表氢或甲基，Z 代表含氮官能团；吡啶嘧啶衍生物作为药用活性剂的用途，特别是用于预防和/或治疗朊病毒感染和朊病毒疾病；以及含有至少一种吡啶嘧啶衍生物和/或其药学上可接受的盐的组合物。此外，本发明还涉及使用所述吡啶嘧啶衍生物预防和/或治疗朊病毒感染和朊病毒疾病的方法。本发明公开了人体细胞蛋白激酶、磷酸酶和细胞信号传导分子，作为检测、预防和/或治疗朊病毒感染和疾病的靶标，特别是可被本发明吡啶嘧啶衍生物抑制的 BSE、vCJD 或 CJD。